Persistent expression of a soluble form of Fas/APO1 in continuously activated T cells from a patient with SLE

Clinical and Experimental Rheumatology

Volumn 15, Issue 1, 1997, Pages 19-23

  Kovacs, B ^a   Szentendrei, T ^b   Bednarek, J M ^b   Pierson, M C ^c   Mountz, J D ^c,d   Vogelgesang, S A ^b   Tsokos, G C ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

autoimmunity; Fas; systemic lupus erythematosus; T cells

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; CELL DEATH; CELL LINE; CULTURE MEDIA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REFERENCE VALUES; SOLUBILITY; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 0030963377     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. NAGATA S, GOLSTEIN P: The Fas death factor. Science 1995; 267: 1449-56.
2. CHENG J, ZHOU T, LIU C, SHAPIRO JP, BRAUER MJ, KIEFER MC, BARR PJ, MOUNTZ JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
3. LIU C, CHENG J, MOUNTZ JD: Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J 1995; 310: 957-63.
4. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
5. TAN EM, COHEN AS, FRES JF, MASI AT, MCSHANE DJ, ROTHFELD NF, SCHALLER JG, TALAL N, WINCHESTER RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271.
6. VASSILOPOULOS D, KOVACS B, TSOKOS GC: T cell receptor/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythemastosus. J Immunol 1995; 155: 2269-81.
7. CHENG J, LIU C, KOOPMAN WJ, MOUNTZ JD: Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995; 154: 1239-45
8. ALDERSON MR, TOUGH TW, DAVIS-SMITH T, BRADDY S, FALK B, SCHOOLEY KA, GOODWIN RG, SMITH CA, RAMSDELL F, LYNCH DH: Fas ligand mediates activation-induced cell death in human T lymphocytes. J ExpMed 1995; 181: 71-7.
9. WU J, ZHOU T, ZHANG J, HE J, GAUSE WC, MOUNTZ JD: Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA 1994; 91: 2344-8.
10. ELKON KB: Apoptosis in SLE - too little or too much? Clin Exp Rheumatol 1994; 12: 553-9.
11. EMLEN W, NIEBUR J, KADERA R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-92.
12. MYSLER E, BINI P, DRAPPA J, RAMOS P, FREIDMAN SM, KRAMMER PH, ELKON KB: The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029-34.
13. KNIPPING E, KRAMMER PH, ONEL KB, LEHMAN TJA, MYSLER E, ELKON KB: Levels of soluble Fas/APO1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38: 1735-7.
14. GOEL N, ULRICH DT, WILLLIAM ST, CLAIR E, FLEMING JA, LYNCH DH, SELDIN MF: Lack of correlation between serum soluble Fas/APO1 levels and autoimmune disease. Arthritis Rheum 1995; 38: 1728-43.